Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

In Vivo Dosimetry During Prostate Cancer Radiotherapy

Phase 1

Completed

Conditions: Prostate Disease

Interventions: Device: Plastic Scintillation Detectors

First Posted Date: 2011-03-03

Last Posted Date: 2016-04-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01307852

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Non-Secretory Plasma Cell Myeloma
Plasmacytosis
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Drug: Panobinostat

First Posted Date: 2011-02-23

Last Posted Date: 2023-09-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT01301807

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Indocyanine Green (IC-Green)
Procedure: Imaging

First Posted Date: 2011-02-15

Last Posted Date: 2015-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01295931

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

Phase 2

Active, not recruiting

Conditions: Transplantation Infection

Interventions: Other: No Cidofovir
Drug: Cidofovir

First Posted Date: 2011-02-14

Last Posted Date: 2025-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT01295645

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Obesity: Cancer Risk Among African Americans

Conditions: Cancer
Obesity

Interventions: Behavioral: Health Education
Behavioral: MAPS

First Posted Date: 2011-02-11

Last Posted Date: 2019-05-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT01294657

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Clofarabine
Drug: Idarubicin
Drug: Cytarabine
Drug: Fludarabine

First Posted Date: 2011-02-03

Last Posted Date: 2020-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 282

Registration Number: NCT01289457

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Prevention of Treatment Induced Neuropathy in Multiple Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Other: Placebo
Drug: Minocycline

First Posted Date: 2011-01-26

Last Posted Date: 2024-06-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 79

Registration Number: NCT01283997

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 2

Completed

Conditions: Advanced Cancers
Sarcoma

Interventions: Procedure: Hyperthermic Peritoneal Perfusion (HIPEC)
Drug: Cisplatin

First Posted Date: 2011-01-17

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01277744

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

Active, not recruiting

Conditions: Peripheral Neuropathy
Pain

Interventions: Behavioral: EEG biofeedback (BF) Group
Behavioral: Wait-List Control (WLC) Group
Behavioral: Follow UP Questionnaires

First Posted Date: 2011-01-17

Last Posted Date: 2025-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT01278225

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

Early Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Losartan

First Posted Date: 2011-01-13

Last Posted Date: 2019-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01276613

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy